Breaking News Instant updates and real-time market news.

QURE

uniQure

$35.08

-4.41 (-11.17%)

, PFE

Pfizer

$37.39

-0.14 (-0.37%)

07:15
07/17/18
07/17
07:15
07/17/18
07:15

uniQure pullback on Pfizer study unwarranted, says H.C. Wainwright

H.C. Wainwright analyst Debjit Chattopadhyay notes that shares of uniQure (QURE) dropped 11% yesterday after Pfizer (PFE) initiated an "open-label, non-investigational product, multi-center, lead-in study to evaluate at least 6 months of prospective efficacy and selected safety data of factor IX prophylaxis replacement therapy in moderate to severe adult Hemophilia B subjects who are negative for neutralizing antibodies to adeno-associated virus vector-spark100". This has been potentially misconstrued as the initiation of the Phase 3 study, suggesting competitive threats for uniQure earlier than anticipated, Chattopadhyay tells investors in a research note. However, this is not to be mistaken as a gene therapy Phase 3 program, as there is no gene therapy treatment cohort, the analyst adds. Further, Chattopadhyay points out that Pfizer's observation study is expected to be completed during November of 2020, which he believes puts uniQure at least a year, if not more, ahead. In addition, the analyst continues to believe that Pfizer is likely to encounter intellectual property headwinds given uniQure's patent asset protecting both the mPadua gene cassette and its method of use to treat hemoglobinopathies. He views the selloff yesterday in shares of uniQure as unwarranted and keeps a Buy rating on the name with a $42 price target.

QURE

uniQure

$35.08

-4.41 (-11.17%)

PFE

Pfizer

$37.39

-0.14 (-0.37%)

  • 22

    Aug

  • 10

    Sep

QURE uniQure
$35.08

-4.41 (-11.17%)

05/24/18
RHCO
05/24/18
INITIATION
Target $48
RHCO
Buy
uniQure initiated with a Buy at SunTrust
SunTrust initiated uniQure with a Buy and $48 price target.
05/24/18
RHCO
05/24/18
INITIATION
Target $48
RHCO
Buy
uniQure initiated with a Buy at SunTrust
As reported earlier, SunTust analyst Edward Nash initiated uniQure with a Buy rating and a price target of $48, saying the company is a "gene therapy pure play initially targeting orphan diseases". He projects the company's revenue for hemophilia B franchise and Huntington's disease reaching as high as $1.4B and over $2B respectively, with 13K U.S./E.U. patients for the former and 100K patients for teh latter. Nash points to Q3 start of testing for uniQure's AMT-061 for hemophilia B as the next potential catalyst for the company.
05/24/18
05/24/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Broadcom (AVGO) initiated with an Outperform at Evercore ISI. 2. Caesars (CZR) initiated with an Overweight at JPMorgan. 3. e.l.f. Beauty (ELF) initiated with an Outperform at Oppenheimer. 4. uniQure (QURE) initiated with a Buy at SunTrust. 5. Marinus Pharmaceuticals (MRNS) initiated with an Outperform at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/27/18
RILY
06/27/18
INITIATION
Target $50
RILY
Buy
uniQure initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Madhu Kumar started uniQure with a Buy rating and $50 price target. The company could dominate hemophilia B adeno-associated viral gene therapy, Kumar tells investors in a research note.
PFE Pfizer
$37.39

-0.14 (-0.37%)

07/11/18
ARGS
07/11/18
NO CHANGE
ARGS
Hold
Pfizer valuation is appropriate, says Argus
Argus analyst David Toung kept his Hold rating on Pfizer, saying the company's valuation at 12.2-times his expected FY19 earnings - below the 12.4-times peer group average for pharmaceutical stocks - is appropriate after its revenue growth slowed in Q1. The analyst notes that higher sales from Eliquis, Ibrance, and Xejanz are being offset by declining sales of drugs faced with a loss of market exclusivity, adding that he remains concerned about competition for Pfizer's key products.
07/11/18
NEED
07/11/18
UPGRADE
Target $5
NEED
Buy
Scynexis upgraded to Buy at Needham after positive phase 2b data for SCY-078
As reported earlier, Needham analyst Alan Carr upgraded Scynexis (SCYX) to Buy from Hold with a price target of $5 after the company's positive Phase 2b trial results of oral SCY-078 in Vulvovaginal Candidiasis. The analyst notes that the data shows the 1-day 300mg BID SCY-078 is "at least equivalent and likely more effective" than the standard 150mg single dose of fluconazole made by Pfizer (PFE). Carr adds that the gastrointestinal tolerability of SCY-078 is also acceptable, which was a key concern in the earlier Phase 2a trial. The analyst further states that the new valuation accounts for expected commercialization of the drug in VVC amid a likely strong interest in a new oral agent suggested by his ObGyn survey last month.
07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
07/16/18
CANT
07/16/18
NO CHANGE
Target $103
CANT
Overweight
Start of Pfizer trial encouraging for Spark Therapeutics, says Cantor Fitzgerald
After Spark Therapeutics (ONCE) announced that partner Pfizer (PFE) initiated a Phase 3 study to evaluate the efficacy and safety of current factor IX prophylaxis replacement therapy in the usual care setting, Cantor Fitzgerald analyst Elemer Piros said he was encouraged that the program transfer is on track and he remains bullish on the fidanacogene elaparvovec program. He reiterates his Overweight rating and $103 price target on Spark shares.

TODAY'S FREE FLY STORIES

ARMK

Aramark

$40.98

3.91 (10.55%)

10:27
08/19/19
08/19
10:27
08/19/19
10:27
Recommendations
Aramark analyst commentary  »

Aramark price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFDL

Security Federal Corp

$0.00

(0.00%)

10:25
08/19/19
08/19
10:25
08/19/19
10:25
Hot Stocks
Security Federal Corp raises quarterly dividend to 10c per share »

Security Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CGC

Canopy Growth

$26.74

-1.36 (-4.84%)

10:25
08/19/19
08/19
10:25
08/19/19
10:25
Options
Canopy Growth call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNMD

Conmed

$95.93

0.93 (0.98%)

10:25
08/19/19
08/19
10:25
08/19/19
10:25
Conference/Events
Conmed participates in a conference call with SVB Leerink »

SVB Leerink hosts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 09

    Sep

ATEC

Alphatec

$6.07

0.08 (1.34%)

10:21
08/19/19
08/19
10:21
08/19/19
10:21
Hot Stocks
Alphatec granted 510(k) premarket notification for Lateral Interbody System »

The FDA judged the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

PRAH

PRA Health

$97.99

0.87 (0.90%)

10:19
08/19/19
08/19
10:19
08/19/19
10:19
Hot Stocks
PRA Health announces strategic alliance between Symphony Health and Close-Up »

PRA Health Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
08/19/19
08/19
10:17
08/19/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
08/19/19
08/19
10:16
08/19/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHAK

Shake Shack

$95.89

-1.17 (-1.21%)

10:15
08/19/19
08/19
10:15
08/19/19
10:15
Options
Shake Shack put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:13
08/19/19
08/19
10:13
08/19/19
10:13
General news
E-Commerce Retail Sales E- Q/Q Change SAAR data reported »

E-Commerce Retail Sales…

NXPI

NXP Semiconductors

$103.80

0.25 (0.24%)

, AMD

AMD

$31.81

0.63 (2.02%)

10:12
08/19/19
08/19
10:12
08/19/19
10:12
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

NXPI

NXP Semiconductors

$103.80

0.25 (0.24%)

AMD

AMD

$31.81

0.63 (2.02%)

NOVA

Sunnova Energy

$11.73

0.69 (6.25%)

XOM

Exxon Mobil

$69.14

0.84 (1.23%)

CVX

Chevron

$117.20

1.41 (1.22%)

COP

ConocoPhillips

$52.92

1.46 (2.84%)

OXY

Occidental Petroleum

$45.15

0.5 (1.12%)

HES

Hess Corp.

$61.42

1.61 (2.69%)

CSTL

Castle Biosciences

$20.77

0.63 (3.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 19

    Aug

  • 20

    Aug

  • 27

    Aug

  • 27

    Aug

  • 10

    Sep

APD

Air Products

$228.62

-0.15 (-0.07%)

, WLL

Whiting Petroleum

$8.65

0.04 (0.46%)

10:12
08/19/19
08/19
10:12
08/19/19
10:12
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

APD

Air Products

$228.62

-0.15 (-0.07%)

WLL

Whiting Petroleum

$8.65

0.04 (0.46%)

CELG

Celgene

$95.15

0.45 (0.48%)

AMGN

Amgen

$204.27

0.32 (0.16%)

ARLP

Alliance Resource Partners

$15.10

0.15 (1.00%)

BTU

Peabody Energy

$19.15

-0.03 (-0.16%)

TRIL

Trillium Therapeutics

$0.29

0.0097 (3.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 27

    Aug

  • 03

    Sep

  • 03

    Sep

  • 09

    Sep

  • 16

    Sep

  • 19

    Sep

  • 23

    Sep

  • 08

    Oct

  • 09

    Oct

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

DECK

Deckers Brands

$138.02

3.69 (2.75%)

, SONO

Sonos

$12.75

0.85 (7.14%)

10:12
08/19/19
08/19
10:12
08/19/19
10:12
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

DECK

Deckers Brands

$138.02

3.69 (2.75%)

SONO

Sonos

$12.75

0.85 (7.14%)

ARMK

Aramark

$40.50

3.43 (9.25%)

ACM

Aecom

$34.02

1.05 (3.18%)

ON

ON Semiconductor

$18.20

0.645 (3.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 13

    Sep

  • 23

    Sep

  • 25

    Sep

LYFT

Lyft

$52.22

-0.15 (-0.29%)

, GOOG

Alphabet

$1,197.73

20.79 (1.77%)

10:05
08/19/19
08/19
10:05
08/19/19
10:05
On The Fly
Lyft rises as lock-up period following IPO ends »

Shares of Lyft (LYFT) are…

LYFT

Lyft

$52.22

-0.15 (-0.29%)

GOOG

Alphabet

$1,197.73

20.79 (1.77%)

GOOGL

Alphabet Class A

$1,199.00

20.31 (1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 24

    Sep

  • 27

    Oct

SE

Sea Limited

$36.60

1.17 (3.30%)

10:05
08/19/19
08/19
10:05
08/19/19
10:05
Options
Sea Limited call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

BMA

Banco Macro

$35.45

-2.83 (-7.39%)

10:00
08/19/19
08/19
10:00
08/19/19
10:00
Hot Stocks
Banco Macro falls -7.4% »

Banco Macro is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$71.80

-6.28 (-8.04%)

10:00
08/19/19
08/19
10:00
08/19/19
10:00
Hot Stocks
Direxion Daily Jr Gld Mnrs Bull 3X Shrs falls -8.2% »

Direxion Daily Jr Gld…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$10.80

-3.5 (-24.48%)

10:00
08/19/19
08/19
10:00
08/19/19
10:00
Hot Stocks
PG&E falls -24.4% »

PG&E is down -24.4%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNT

Unit Corp.

$3.58

0.35 (10.84%)

10:00
08/19/19
08/19
10:00
08/19/19
10:00
Hot Stocks
Unit Corp. rises 9.7% »

Unit Corp. is up 9.7%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

BE

Bloom Energy

$5.61

0.5 (9.78%)

10:00
08/19/19
08/19
10:00
08/19/19
10:00
Hot Stocks
Bloom Energy rises 9.9% »

Bloom Energy is up 9.9%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARMK

Aramark

$40.78

3.71 (10.01%)

10:00
08/19/19
08/19
10:00
08/19/19
10:00
Hot Stocks
Aramark rises 9.9% »

Aramark is up 9.9%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QSR

Restaurant Brands

$74.89

0.36 (0.48%)

09:56
08/19/19
08/19
09:56
08/19/19
09:56
Recommendations
Restaurant Brands analyst commentary  »

SSS at Restaurant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGNA

Tegna

$15.70

0.62 (4.11%)

, APO

Apollo Global

$34.18

2.15 (6.71%)

09:56
08/19/19
08/19
09:56
08/19/19
09:56
Hot Stocks
Tegna jumps after report of Apollo deal interest »

Shares of Tegna (TGNA)…

TGNA

Tegna

$15.70

0.62 (4.11%)

APO

Apollo Global

$34.18

2.15 (6.71%)

NXST

Nexstar

$96.12

2.07 (2.20%)

TRCO

Tribune Media

$46.48

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 23

    Sep

  • 13

    Nov

EL

Estee Lauder

$193.74

14.48 (8.08%)

, DO

Diamond Offshore

$6.19

0.365 (6.27%)

09:55
08/19/19
08/19
09:55
08/19/19
09:55
Options
Early notable gainers among liquid option names on August 19th »

Notable gainers among…

EL

Estee Lauder

$193.74

14.48 (8.08%)

DO

Diamond Offshore

$6.19

0.365 (6.27%)

NVDA

Nvidia

$166.49

7.01 (4.40%)

WYNN

Wynn Resorts

$109.82

4.24 (4.02%)

TGNA

Tegna

$15.61

0.53 (3.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 19

    Aug

  • 20

    Aug

  • 27

    Aug

  • 05

    Sep

  • 09

    Sep

  • 23

    Sep

PCG

PG&E

$11.12

-3.18 (-22.24%)

09:52
08/19/19
08/19
09:52
08/19/19
09:52
Downgrade
PG&E rating change  »

Citi double downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.